PHARMING GROUP N.V. |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.91 EUR | +0.22% |
|
-5.26% | -11.74% |
| Apr. 22 | Pharming Group to Buy Back EUR123 Million of Bonds due 2025 | MT |
| Apr. 18 | Pharming Group to Issue EUR100 Million Convertible Bonds, Repurchase EUR125 Million Bonds | MT |
ETFs positioned on Pharming Group N.V.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.17% | 2 M€ | -.--% | ||
| 0.05% | 7 M€ | -.--% | - | |
| 0.02% | 773 M€ | -.--% | - | |
| 0.01% | 10 M€ | -3.35% | - | |
| 0.00% | 1 M€ | -.--% | - | |
| 0.00% | 29 M€ | -2.71% | - | |
| 0.00% | 152 M€ | -3.20% | - | |
| 0.00% | 26 M€ | 0.00% | - |
Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The Group is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development.
Pharming Group N.V. serves patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia/Pacific.
Sector
Pharmaceuticals
Calendar
2024-05-08
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.908
EUR
Average target price
2
EUR
Spread / Average Target
+120.26%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.74% | 654M | |
| +27.92% | 672B | |
| +27.26% | 570B | |
| -4.59% | 360B | |
| +16.38% | 321B | |
| +9.39% | 300B | |
| +7.51% | 217B | |
| +5.54% | 199B | |
| -8.43% | 204B | |
| -8.58% | 149B |
- Stock Market
- Equities
- PHARM Stock
- Funds and ETFs Pharming Group N.V.
